| P50 | author | Mark Wainberg | Q3294273 |
| | Michel Roger | Q57303410 |
| | Bluma Brenner | Q60299886 |
| | Hugues Charest | Q86870110 |
| | Cécile Tremblay | Q88627432 |
| | Daniela Moisi | Q115623576 |
| | Jean-Guy Baril | Q121183517 |
| | Isabelle Hardy | Q122902540 |
| P2093 | author name string | Donald G Murphy | |
| | Ernest Lo | |
| | Florence Doualla-Bell | |
| | Linda Lemieux | |
| | Régis Cantin | |
| P2860 | cites work | Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study. | Q51914235 |
| | Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy. | Q54397378 |
| | Reduced emergence of the M184V/I resistance mutation when antiretroviral-naïve subjects use emtricitabine versus lamivudine in regimens composed of two NRTIs plus the NNRTI efavirenz. | Q54596202 |
| | Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 |
| | Prevention of HIV-1 infection with early antiretroviral therapy | Q24634688 |
| | Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009 | Q28476489 |
| | Sentinel surveillance of HIV-1 transmitted drug resistance, acute infection and recent infection | Q28477399 |
| | Recent HIV-1 infection contributes to the viral diffusion over the French territory with a recent increasing frequency | Q28480667 |
| | Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010 | Q28481603 |
| | Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients | Q28483630 |
| | Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group | Q29614934 |
| | Brief but efficient: acute HIV infection and the sexual transmission of HIV. | Q30341429 |
| | Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco | Q33604727 |
| | Treatment to prevent transmission of HIV-1 | Q34102424 |
| | Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study | Q34126545 |
| | Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine | Q35021860 |
| | A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies | Q35742512 |
| | Prevalence of transmitted antiretroviral drug resistance differs between acutely and chronically HIV-infected patients | Q36279238 |
| | Transmission networks of drug resistance acquired in primary/early stage HIV infection | Q37115372 |
| | Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. | Q37175647 |
| | Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis | Q37531320 |
| | Preventing HIV transmission through antiretroviral treatment-mediated virologic suppression: aspects of an emerging scientific agenda | Q37974036 |
| | Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. | Q37980615 |
| | The prevalence of antiretroviral drug resistance in the United States | Q39687529 |
| | High rates of forward transmission events after acute/early HIV-1 infection | Q39788342 |
| | The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection | Q39887453 |
| | Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management | Q40396257 |
| | Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens | Q42925586 |
| | Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: Nationwide surveillance from 2003 to 2008 in Japan | Q44103745 |
| | Decline in deaths from AIDS due to new antiretrovirals | Q44184848 |
| | Transmission of drug-resistant HIV-1 is stabilizing in Europe | Q44591236 |
| | Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland | Q45069480 |
| | Transmission network of an HIV type 1 strain with K103N in young Belgian patients from different risk groups | Q45114115 |
| | In vivo dynamics of the K103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in Human Immunodeficiency Virus-infected patients | Q45421198 |
| | Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens | Q45811702 |
| | Antiretroviral-drug resistance among patients recently infected with HIV. | Q46277555 |
| | Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. | Q46520376 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | viral load | Q2528140 |
| P304 | page(s) | e109420 | |
| P577 | publication date | 2014-01-01 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | A significant reduction in the frequency of HIV-1 drug resistance in Québec from 2001 to 2011 is associated with a decrease in the monitored viral load | |
| P478 | volume | 9 | |